- Home
- ZI vs KRYS Comparison
ZI vs KRYS Comparison
Compare ZI & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZI
- KRYS
- Stock Information
- Founded
- ZI 2007
- KRYS 2015
- Country
- ZI United States
- KRYS United States
- Employees
- ZI N/A
- KRYS N/A
- Industry
- ZI Computer Software: Prepackaged Software
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZI Technology
- KRYS Health Care
- Exchange
- ZI Nasdaq
- KRYS Nasdaq
- Market Cap
- ZI 4.6B
- KRYS 4.9B
- IPO Year
- ZI 2020
- KRYS 2017
- Fundamental
- Price
- ZI $10.37
- KRYS $182.29
- Analyst Decision
- ZI Hold
- KRYS Strong Buy
- Analyst Count
- ZI 21
- KRYS 7
- Target Price
- ZI $13.33
- KRYS $206.00
- AVG Volume (30 Days)
- ZI 10.8M
- KRYS 266.2K
- Earning Date
- ZI 11-12-2024
- KRYS 11-04-2024
- Dividend Yield
- ZI N/A
- KRYS N/A
- EPS Growth
- ZI N/A
- KRYS N/A
- EPS
- ZI 0.02
- KRYS 1.77
- Revenue
- ZI $1,221,600,000.00
- KRYS $241,519,000.00
- Revenue This Year
- ZI N/A
- KRYS $485.65
- Revenue Next Year
- ZI $0.73
- KRYS $58.64
- P/E Ratio
- ZI $429.74
- KRYS $102.59
- Revenue Growth
- ZI N/A
- KRYS 2722.80
- 52 Week Low
- ZI $7.65
- KRYS $99.00
- 52 Week High
- ZI $19.39
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- ZI 46.14
- KRYS 52.22
- Support Level
- ZI $9.52
- KRYS $168.88
- Resistance Level
- ZI $10.80
- KRYS $207.84
- Average True Range (ATR)
- ZI 0.56
- KRYS 9.66
- MACD
- ZI -0.19
- KRYS -0.29
- Stochastic Oscillator
- ZI 21.96
- KRYS 42.16
About ZI ZoomInfo Technologies Inc
ZoomInfo Technologies Inc provides a go-to-market intelligence platform for sales and marketing teams. Its cloud-based go-to-market data and insights platform deliver comprehensive and high-quality intelligence and analytics to provide sales and marketing professionals with accurate information and insights on the organizations and professionals. Nearly all of its revenue is derived from the United States.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.